09-430 | Anti-phospho-IRS1 (Ser636/Ser639) Antibody

200 µL  
Retrieving price...
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
Request Pricing
Limited AvailabilityLimited Availability
In Stock 
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service

      Special Offers


      Contact Customer Service

      Click To Print This Page


      Replacement Information

      Key Spec Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      H, Ca, Ch, M, Eq, RWBRbPurifiedPolyclonal Antibody
      Catalogue Number09-430
      DescriptionAnti-phospho-IRS1 (Ser636/Ser639) Antibody
      Alternate Names
      • insulin receptor substrate 1
      Background InformationInsulin receptor substrate 1, also known as IRS1, is associated with various cellular processes involved in the production of insulin. IRS1 transmits insulin signals via metabolic and mitogenic pathways. IRS1 is a docking protein that binds SH2 domains such as phosphatidylinositol 3-kinase p85 subunit or GRB2, resulting in activation. Over expression and phosphorylation of serine is associated with insulin resistance and breast cancer. mTOR induces the phosphorylation of IRS-1 at Ser636/639m whereas such phosphorylation is inhibited by rapamycin.
      Product Information
      • IRS1 transfected CHO +/- Insulin lysate.
      PresentationPurified rabbit polyclonal in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.
      ApplicationThis Anti-phospho-IRS1 (Ser636/Ser639) Antibody is validated for use in WB for the detection of phospho-IRS1 (Ser636/Ser639).
      Key Applications
      • Western Blotting
      Biological Information
      ImmunogenKLH-conjugated synthetic linear peptide corresponding to amino acids at and around phosphorylated Ser636 and Ser639 of human IRS1.
      EpitopePhosphorylated Ser636/Ser639
      ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
      SpecificityThis antibody recognizes IRS1 phosphorylated at Ser636/Ser639.
      Species Reactivity
      • Human
      • Canine
      • Chicken
      • Mouse
      • Horse
      • Rat
      Species Reactivity NoteHuman. Predicted to cross-react with mouse, rat, equine (horse), canine (dog) and chicken based on sequence homology.
      Antibody TypePolyclonal Antibody
      Entrez Gene Number
      Gene Symbol
      • HIRS-1
      • IRS-1
      • Phosphorylation
      Purification MethodAffinity Purfied
      UniProt Number
      UniProt SummaryFUNCTION: May mediate the control of various cellular processes by insulin. When phosphorylated by the insulin receptor binds specifically to various cellular proteins containing SH2 domains such as phosphatidylinositol 3-kinase p85 subunit or GRB2. Activates phosphatidylinositol 3-kinase when bound to the regulatory p85 subunit By similarity.

      SUBUNIT: structure Interacts with the NPXY motif of tyrosine-phosphorylated IGF1R and INSR via the PTB domain. Binds to phosphatidylinositol 3-kinase p85 subunit via the phosphorylated YXXM motifs. Binds ROCK1. Binds to UBTF and PIK3CA in nuclear extracts By similarity. Interacts with SOCS7.

      PTM: Serine phosphorylation of IRS1 is a mechanism for insulin resistance. Ser-312 phosphorylation inhibits insulin action through disruption of IRS1 interaction with the insulin receptor By similarity.

      Phosphorylation of Tyr-896 is required for GRB2-binding By similarity.

      Polymorphism The Arg-971 polymorphism impairs the ability of insulin to stimulate glucose transport, glucose transporter translocation, and glycogen synthesis by affecting the PI3K/AKT1/GSK3 signaling pathway. The polymorphism at Arg-971 may contribute to the in vivo insulin resistance observed in carriers of this variant. Arg-971 could contribute to the risk for atherosclerotic cardiovascular diseases associated with non-insulin-dependent diabetes mellitus (NIDDM) by producing a cluster of insulin resistance-related metabolic abnormalities. In insulin-stimulated human endothelial cells from carriers of the Arg-971 polymorphism, genetic impairment of the IRS1/PI3K/PDPK1/AKT1 insulin signaling cascade results in impaired insulin-stimulated nitric oxide (NO) release and suggested that this may be a mechanism through which the Arg-971 polymorphism contributes to the genetic predisposition to develop endothelial dysfunction and cardiovascular disease. The Arg-971 polymorphism not only reduces phosphorylation of the substrate but allows IRS1 to act as an inhibitor of PI3K, producing global insulin resistance.

      DISEASE: Polymorphisms in IRS1 may be involved in the etiology of non-insulin-dependent diabetes mellitus (NIDDM) [MIM:125853]. Ref.18 Ref.19 Ref.21 Ref.24 Ref.25

      SIMILARITY: Contains 1 IRS-type PTB domain.

      Contains 1 PH domain.

      Molecular Weight~185 kDa.
      Nonspecific bands may be detected at ~85, 70 and 55 kDa.
      Physicochemical Information
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality AssuranceEvaluated by western blot on IRS1 transfected CHO +/- Insulin lysate.

      Western Blot Analysis:
      1:500 dilution of this antibody was used to detect IRS1 phosphorylated on Ser636/Se639 in IRS transfected CHO +/- Insulin lysate.
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsStable for 1 year at 2-8ºC from date of receipt.
      Packaging Information
      Material Size200 µL
      Transport Information
      Supplemental Information